Committee Action
On June 14, 2023, the Subcommittee on Health held a hearing
on H.R. 3884. The Subcommittee received testimony from:
Dr. Elizabeth Cherot, MD, MBA, Senior Vice
President and Chief Medical Health Officer, March of
Dimes;
Dr. Alexis A. Thompson, MD, MPH, Chief of
Division of Hematology, Elias Schwartz MD Endowed Chair
in Hematology, Children's Hospital of Philadelphia,
Professor of Pediatrics, University of Pennsylvania
Perelman School of Medicine;
Dr. Meredithe McNamara, MD, MS, FAAP,
Assistant Professor, Yale School of Medicine;
Dr. Miriam Grossman, MD, Child, Adolescent,
and Adult Psychiatrist;
Mr. George Manahan, Parkinson's Advocate and
Patient; and,
Mr. Kevin O'Connor, Assistant to the General
President for Government Affairs and Political Action,
International Association of Fire Fighters.
On July 13, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 3884, as amended, to the full
Committee by a record vote of 28 yeas and 0 nays. On July 19,
2023, the full Committee on Energy and Commerce met in open
markup session and ordered H.R. 3884, as amended, favorably
reported to the House by a record vote of 50 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
reauthorize sickle cell programs and activities under CDC and
HRSA to support efforts to provide services, education,
training, and best practices related to identification,
prevention, and treatment of sickle cell disease.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 3884 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 3884:
On June 14, 2023, the Subcommittee on Health
held a hearing on H.R. 3884. The Subcommittee received
testimony from:
Dr. Elizabeth Cherot, MD, MBA,
Senior Vice President and Chief Medical Health
Officer, March of Dimes;
Dr. Alexis A. Thompson, MD, MPH,
Chief of Division of Hematology, Elias Schwartz
MD Endowed Chair in Hematology, Children's
Hospital of Philadelphia, Professor of
Pediatrics, University of Pennsylvania Perelman
School of Medicine;
Dr. Meredithe McNamara, MD, MS,
FAAP, Assistant Professor, Yale School of
Medicine;
Dr. Miriam Grossman, MD, Child,
Adolescent, and Adult Psychiatrist;
Mr. George Manahan, Parkinson's
Advocate and Patient; and,
Mr. Kevin O'Connor, Assistant to
the General President for Government Affairs
and Political Action, International Association
of Fire Fighters.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 3884 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``Sickle Cell Disease
and Other Heritable Blood Disorders Research, Surveillance,
Prevention, and Treatment Act of 2023''.
Section 2. Reauthorization of sickle cell disease and other heritable
blood disorders research, surveillance, prevention, and
treatment
Section 2 amends Title XI of the Public Health Service Act
to reauthorize the program providing for sickle cell disease
and other heritable blood disorders research, surveillance,
prevention, and treatment, for fiscal years 2024 through 2028.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
TITLE XI--GENETIC DISEASES, HEMOPHILIA PROGRAMS, AND SUDDEN INFANT
DEATH SYNDROME
Part A--Genetic Diseases
* * * * * * *
SEC. 1106. SICKLE CELL DISEASE AND OTHER HERITABLE BLOOD DISORDERS
RESEARCH, SURVEILLANCE, PREVENTION, AND TREATMENT.
(a) Grants.--
(1) In general.--The Secretary may award grants
related to heritable blood disorders, including sickle
cell disease, for one or more of the following
purposes:
(A) To collect and maintain data on such
diseases and conditions, including subtypes as
applicable, and their associated health
outcomes and complications, including for the
purpose of--
(i) improving national incidence and
prevalence data;
(ii) identifying health disparities,
including the geographic distribution,
related to such diseases and
conditions;
(iii) assessing the utilization of
therapies and strategies to prevent
complications; and
(iv) evaluating the effects of
genetic, environmental, behavioral, and
other risk factors that may affect such
individuals.
(B) To conduct public health activities with
respect to such conditions, which may include--
(i) developing strategies to improve
health outcomes and access to quality
health care for the screening for, and
treatment and management of, such
diseases and conditions, including
through public-private partnerships;
(ii) providing support to community-
based organizations and State and local
health departments in conducting
education and training activities for
patients, communities, and health care
providers concerning such diseases and
conditions;
(iii) supporting State health
departments and regional laboratories,
including through training, in testing
to identify such diseases and
conditions, including specific forms of
sickle cell disease, in individuals of
all ages; and
(iv) the identification and
evaluation of best practices for
treatment of such diseases and
conditions, and prevention and
management of their related
complications.
(2) Population included.--The Secretary shall, to the
extent practicable, award grants under this subsection
to eligible entities across the United States to
improve data on the incidence and prevalence of
heritable blood disorders, including sickle cell
disease, and the geographic distribution of such
diseases and conditions.
(3) Application.--To seek a grant under this
subsection, an eligible entity shall submit an
application to the Secretary at such time, in such
manner, and containing such information as the
Secretary may require.
(4) Priority.--In awarding grants under this
subsection, the Secretary may give priority, as
appropriate, to eligible entities that have a
relationship with a community-based organization that
has experience in, or is capable of, providing services
to individuals with heritable blood disorders,
including sickle cell disease.
(5) Eligible entity.--In this subsection, the term
``eligible entity'' includes the 50 States, the
District of Columbia, the Commonwealth of Puerto Rico,
the United States Virgin Islands, the Commonwealth of
the Northern Mariana Islands, American Samoa, Guam, the
Federated States of Micronesia, the Republic of
Marshall Islands, the Republic of Palau, Indian tribes,
a State or local health department, an institution of
higher education, or a nonprofit entity with
appropriate experience to conduct the activities under
this subsection.
(b) Demonstration Program for the Development and
Establishment of Systemic Mechanisms for the Prevention and
Treatment of Sickle Cell Disease.--
(1) Authority to conduct demonstration program.--
(A) In general.--The Administrator, through
the Bureau of Primary Health Care and the
Maternal and Child Health Bureau, shall
continue efforts, including by awarding grants,
to develop or establish mechanisms to improve
the treatment of sickle cell disease, and to
improve the prevention and treatment of
complications of sickle cell disease, in
populations with a high proportion of
individuals with sickle cell disease, including
through--
(i) the coordination of service
delivery for individuals with sickle
cell disease;
(ii) genetic counseling and testing;
(iii) bundling of technical services
related to the prevention and treatment
of sickle cell disease;
(iv) training of health
professionals; and
(v) identifying and establishing
other efforts related to the expansion
and coordination of education,
treatment, and continuity of care
programs for individuals with sickle
cell disease.
(B) Geographic diversity.--The Administrator
shall, to the extent practicable, award grants
under this section to eligible entities located
in different regions of the United States.
(2) Additional requirements.--An eligible entity
awarded a grant under this subsection shall use funds
made available under the grant to carry out, in
addition to the activities described in paragraph
(1)(A), the following activities:
(A) To facilitate and coordinate the delivery
of education, treatment, and continuity of care
for individuals with sickle cell disease
under--
(i) the entity's collaborative
agreement with a community-based sickle
cell disease organization or a
nonprofit entity that works with
individuals who have sickle cell
disease;
(ii) the sickle cell disease newborn
screening program for the State in
which the entity is located; and
(iii) the maternal and child health
program under title V of the Social
Security Act (42 U.S.C. 701 et seq.)
for the State in which the entity is
located.
(B) To train nursing and other health staff
who provide care for individuals with sickle
cell disease.
(C) To enter into a partnership with adult or
pediatric hematologists in the region and other
regional experts in sickle cell disease at
tertiary and academic health centers and State
and county health offices.
(D) To identify and secure resources for
ensuring reimbursement under the medicaid
program, State children's health insurance
program, and other health programs for the
prevention and treatment of sickle cell
disease.
(E) To provide or coordinate services for
adolescents with sickle cell disease making the
transition to adult health care.
(3) National coordinating center.--
(A) Establishment.--The Administrator shall
enter into a contract, grant, or cooperative
agreement with an entity to serve as the
National Coordinating Center for the
demonstration program conducted under this
subsection.
(B) Activities described.--The National
Coordinating Center shall--
(i) collect, coordinate, monitor, and
distribute data, best practices, and
findings regarding the activities
funded under grants made to eligible
entities under the demonstration
program;
(ii) develop a model protocol for
eligible entities with respect to the
prevention and treatment of sickle cell
disease;
(iii) develop educational materials
regarding the prevention and treatment
of sickle cell disease; and
(iv) prepare and submit to Congress a
final report that includes
recommendations regarding the
effectiveness of the demonstration
program conducted under this subsection
and such direct outcome measures as--
(I) the number and type of
health care resources utilized
(such as emergency room visits,
hospital visits, length of
stay, and physician visits for
individuals with sickle cell
disease); and
(II) the number of
individuals that were tested
and subsequently received
genetic counseling for the
sickle cell trait.
(4) Application.--An eligible entity desiring a grant
under this subsection shall submit an application to
the Administrator at such time, in such manner, and
containing such information as the Administrator may
require.
(5) Definitions.--In this subsection:
(A) Administrator.--The term
``Administrator'' means the Administrator of
the Health Resources and Services
Administration.
(B) Eligible entity.--The term ``eligible
entity'' means a Federally-qualified health
center, a nonprofit hospital or clinic, or a
university health center that provides primary
health care, that--
(i) has a collaborative agreement
with a community-based sickle cell
disease organization or a nonprofit
entity with experience in working with
individuals who have sickle cell
disease; and
(ii) demonstrates to the
Administrator that either the
Federally-qualified health center, the
nonprofit hospital or clinic, the
university health center, the
organization or entity described in
clause (i), or the experts described in
paragraph (2)(C), has at least 5 years
of experience in working with
individuals who have sickle cell
disease.
(C) Federally-qualified health center.--The
term ``Federally-qualified health center'' has
the meaning given that term in section
1905(l)(2)(B) of the Social Security Act (42
U.S.C. 1396d(l)(2)(B)).
(6) Authorization of appropriations.--There is
authorized to be appropriated to carry out this
subsection, [$4,455,000 for each of fiscal years 2019
through 2023] $8,205,000 for each of fiscal years 2024
through 2028.
* * * * * * *